| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
0.94 |
| Autoimmune Disease |
0 |
0.99 |
| Healthcare and Medical Technology |
0 |
0.43 |
| Systemic Lupus Erythematosus |
0 |
0.43 |
| Clinical Research |
0 |
0.28 |
| T-Cell Receptor |
0 |
0.22 |
| Antigens |
0 |
0.21 |
| Receptors |
0 |
0.21 |
| Immunotherapy |
0 |
0.17 |
| Lupus |
0 |
0.17 |
| Toxicology |
0 |
0.16 |
| Antineoplastic Drug |
0 |
0.14 |
| Biomedical Technology |
0 |
0.14 |
| Lupus Nephritis |
0 |
0.14 |
| Muscular Atrophy |
0 |
0.14 |
| Myasthenia Gravis |
0 |
0.14 |
| Tissue |
0 |
0.14 |
| Patient Safety |
0 |
0.13 |
| Leukemia |
0 |
0.12 |
| Targeted Cancer Therapy |
0 |
0.11 |
| Cancer |
0 |
0.1 |
| Monoclonal Antibody |
0 |
0.1 |
| Myositis |
0 |
0.1 |
| Pennsylvania |
0 |
0.1 |
| Plasma |
0 |
0.1 |
| Refractory |
0 |
0.1 |
| Revenue and Practice Management |
0 |
0.09 |
| CT Scan |
0 |
0.08 |
| Rheumatoid Arthritis |
0 |
0.08 |
| Adverse Effects |
0 |
0.07 |
| Antiphospholipid Syndrome |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Cytokines |
0 |
0.07 |
| Grant |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Multiple Sclerosis |
0 |
0.07 |
| Pemphigus Vulgaris |
0 |
0.07 |
| Remission |
0 |
0.07 |